Innate Pharma: AZN should come back… and it may be better than expected
BUY, Fair Value EUR19 (+40%)We reiterate our positive stance regarding the potential of IPH2201 as an add-on for the durvalumab franchise following a meeting with Pierre Dordion (IPH’s Chief Medical Officer). Our base-case scenario on the future development of IPH2201/durvalumab is not only confirmed… but may exceed our current expectations (either in solid tumors or in haematological malignancies).
For more information, please contact marketing@bryangarnier.com